|Systematic (IUPAC) name|
|Melt. point||66 °C (151 °F)|
CBD alone is not intoxicating, but it appears to affect the euphoric effect of THC (which is an isomer of cannabidiol) and add a sedative quality . Some research, however, indicates that CBD can increase alertness. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver. CBD does not appear to affect either the CB1 or CB2 receptors.
Medically, it appears to relieve convulsion, inflammation, anxiety, and nausea, as well as inhibit cancer cell growth. Recent studies have shown cannabidiol to be as effective as atypical antipsychotics in treating schizophrenia.
In April 2005, Canadian authorities approved the marketing of Sativex, a mouth spray for multiple sclerosis to alleviate pain. Sativex contains tetrahydrocannabinol together with cannabidiol. It is marketed in Canada by GW Pharmaceuticals.
Cannabidiol has also been shown to inhibit cancer cell growth, with low potency in non-cancer cells. Although the inhibitory mechanism is not yet fully understood, Ligresti et al suggest that "cannabidiol exerts its effects on these cells through a combination of mechanisms that include either direct or indirect activation of CB2 and TRPV1 receptors, and induction of oxidative stress, all contributing to induce apoptosis."
- ↑ Grlie, L (1976). "A comparative study on some chemical and biological characteristics of various samples of cannabis resin.". Bulletin on Narcotics 14: 37-46.
- ↑ Nicholson, AN; C Turner, BM Stone, and PJ Robson (June 2004). "Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults" (fee required). J Clin Psychopharmacol 24 (3): 305-13. ISSN 0271-0749. PMID 15118485. Retrieved on 2007-05-03.
- ↑ Straus, Stephen E. (15 August 2000). "Immunoactive cannabinoids: Therapeutic prospects for marijuana constituents". Proc Natl Acad Sci U S A. 97 (17): 9363–9364.
- ↑ Zuardi, A.W; J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira, F.S. Guimarães (2006). "Cannabidiol as an antipsychotic drug". Brazilian Journal of Medical and Biological Research 39: 421-429. ISSN 0100-879X ISSN 0100-879X.
- ↑ Ligresti, Alessia; Aniello Schiano Moriello, Katarzyna Starowicz, Isabel Matias, Simona Pisanti, Luciano De Petrocellis, Chiara Laezza, Giuseppe Portella, Maurizio Bifulco, and Vincenzo Di Marzo (2006-05-25). "[http://jpet.aspetjournals.org/cgi/reprint/jpet.106.105247v1 Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma]". Journal of Pharmacology and Experimental Therapeutics Fast Forward (May 2006): 50. American Society of Pharmacology and Experimental Therapeutics. doi:10.1124. jpet.106.105247. Retrieved on 2007-05-03.
- Cannabinoid receptors
- Health issues and the effects of cannabis
- Medical marijuana
- Erowid Compounds found in Cannabis sativa
|Plant cannabinoids||CBD • CBDV • CBN • CBG • CBV • CBL • THC • THC-C4 • THCV|
|Cannabinoid metabolites||11-Hydroxy-THC • 11-nor-9-Carboxy-THC|
|Endogenous cannabinoids||Arachidonoyl ethanolamide (Anandamide or AEA) • 2-Arachidonoylglycerol (2-AG) • 2-Arachidonyl glyceryl ether (noladin ether) • Virodhamine • N-arachidonoyl-dopamine (NADA)|
|Synthetic cannabinoid agonists|
|Endocannabinoid activity enhancers|
|Cannabinoid antagonists and inverse agonists|
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies